ArticleHypertension research : official journal of the Japanese Society of Hypertension2022
Cost-effectiveness of digital therapeutics for essential hypertension.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Smartphone application-based intervention to lower blood pressure: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Economic Evaluation Associated With Clinical-Grade Mobile App-Based Digital Therapeutic Interventions: Systematic Review.Journal of medical Internet research · 2023Pooled it
- Effects of Artificial Intelligence Recognition-Based Telerehabilitation on Exercise Capacity in Patients With Hypertension: Randomized Controlled Trial.Journal of medical Internet research · 2026Trial
- Cost-Utility Analysis and Value-Based Pricing of Digital Therapeutics for Pulmonary Rehabilitation in Chronic Respiratory Disease: Economic Evaluation Based on a Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Internet-based digital intervention to support the self-management of hypertension compared to usual care: results of the HALCYON randomized controlled trial.BMC cardiovascular disorders · 2025Trial
- Review
- The Japanese Society of Hypertension Guidelines for blood pressure control using digital technologies.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Investigating feature-engineered predictors for systolic blood pressure changes in an mHealth-based disease management program.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan.International journal of hematology · 2026Article
- Digital therapeutics and mHealth applications in cardiovascular prevention: strongest evidence in hypertension and emerging perspectives in dyslipidemia.Frontiers in digital health · 2026Review
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Health economic evaluations of digital health technologies-a rapid review of applied methods.Frontiers in digital health · 2026Review
- Digital hypertension - what we need for the high-quality management of hypertension in the new era.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Evaluating the Clinical Effectiveness and Patient Experience of a Large Language Model-Based Digital Tool for Home-Based Blood Pressure Management: Mixed Methods Study.JMIR mHealth and uHealth · 2025Article
- Artificial Intelligence and Advanced Digital Health for Hypertension: Evolving Tools for Precision Cardiovascular Care.Medicina (Kaunas, Lithuania) · 2025Review
- GAIT-CKD (Gait Analysis using Artificial Intelligence for digital Therapeutics of patients with Chronic Kidney Disease): design and methods.Kidney research and clinical practice · 2025Article
- A Digital Software Support Platform for Hyperthyroidism Management in South Korea: Markov Simulation Model-Based Cost-Effectiveness Analysis.JMIR mHealth and uHealth · 2025Article
- CureAPP HT is expected to be one piece of the puzzle that physicians and patients can work together to solve the problem of uncontrolled hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Advances in digital technology in healthcare.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- App-based multimodal lifestyle-intervention for essential hypertension (HYPE): a decentralized randomised controlled trial.Frontiers in digital health · 2025Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension increases the risk of cardiovascular and other diseases. Lifestyle modification is a significant component of nonpharmacological treatments for hypertension. We previously reported the clinical efficacy of digital therapeutics (DTx) in the HERB-DH1 trial. However, there is still a lack of cost-effectiveness assessments evaluating the impact of prescription DTx. This study aimed to analyze the cost-effectiveness of using prescription DTx in treating hypertension. We developed a monthly cycle Markov model and conducted Monte Carlo simulations using the HERB-DH1 trial data to investigate quality-adjusted life-years (QALYs) and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation treatment as usual (TAU), comparing DTx + TAU and TAU-only groups with a lifetime horizon. The model inputs were obtained from the HERB-DH1 trial, published or publicly available data, and expert assumptions. The incremental cost-effectiveness ratio (ICER) per QALY was used as the benchmark for cost-effectiveness. We performed probabilistic sensitivity analyses (PSAs) using the Monte Carlo simulation with two million sets. The DTx + TAU strategy produced 18.778 QALYs and was associated with ¥3,924,075 ($34,122) expected costs, compared with 18.686 QALYs and ¥3,813,358 ($33,160) generated by the TAU-only strategy over a lifetime horizon, resulting in an ICER of ¥1,199,880 ($10,434)/QALY gained for DTx + TAU. The monthly cost and attrition rate of DTx for hypertension have a significant impact on ICERs. In the PSA, the probability of the DTx arm being a cost-effective option was 87.8% at a threshold value of ¥5 million ($43,478)/QALY gained. In conclusion, the DTx + TAU strategy was more cost-effective than the TAU-only strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.